Zacks Research Estimates Novavax’s Q3 Earnings (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) – Research analysts at Zacks Research cut their Q3 2026 earnings per share estimates for Novavax in a research note issued on Wednesday, August 26th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn ($0.33) per share for the quarter, down from their prior estimate of $0.08. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Novavax’s current full-year earnings is ($0.43) per share. Zacks Research also issued estimates for Novavax’s Q4 2026 earnings at $0.49 EPS, FY2026 earnings at ($0.23) EPS, Q1 2027 earnings at ($0.27) EPS, Q2 2027 earnings at $0.13 EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.58) EPS, Q1 2028 earnings at ($0.11) EPS, Q2 2028 earnings at ($0.17) EPS and FY2028 earnings at $0.78 EPS.

Other research analysts also recently issued research reports about the stock. TD Cowen upped their target price on shares of Novavax from $8.00 to $9.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. Wall Street Zen downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. BTIG Research reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research report on Thursday, June 11th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Novavax in a research note on Tuesday, August 4th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $14.00.

Novavax Stock Performance

NASDAQ:NVAX opened at $9.05 on Friday. The firm has a market cap of $1.49 billion, a P/E ratio of -5.95 and a beta of 2.46. Novavax has a fifty-two week low of $6.20 and a fifty-two week high of $11.97. The firm has a 50-day simple moving average of $8.47 and a two-hundred day simple moving average of $8.93.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The company had revenue of $56.70 million for the quarter, compared to analysts’ expectations of $52.51 million. During the same quarter in the previous year, the business posted $0.62 EPS. Novavax’s revenue was down 76.2% compared to the same quarter last year.

Institutional Trading of Novavax

A number of institutional investors have recently made changes to their positions in NVAX. Quarry LP bought a new stake in shares of Novavax in the third quarter worth approximately $33,000. Duncker Streett & Co. Inc. boosted its holdings in Novavax by 917.3% in the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 3,825 shares during the last quarter. KBC Group NV boosted its holdings in Novavax by 34.9% in the first quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 1,229 shares during the last quarter. State of Wyoming bought a new stake in Novavax in the 2nd quarter worth approximately $52,000. Finally, Danske Bank A S purchased a new stake in Novavax during the 3rd quarter valued at $64,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Key Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: The FDA approved Novavax-Sanofi’s updated COVID-19 vaccine for the 2026–27 season, targeting the dominant XFG variant. The approval preserves Novavax’s participation in the U.S. COVID vaccine market, although eligibility is limited primarily to adults 65 and older and people with high-risk conditions. Reuters FDA vaccine approval article
• Neutral Sentiment: Novavax CEO John C. Jacobs was appointed to the board of Ambros Therapeutics, a move that highlights his industry experience but has no immediate financial impact on Novavax. Ambros Therapeutics board appointments article
• Negative Sentiment: Zacks Research made broad downward revisions to Novavax’s earnings outlook. Estimates were cut for Q3 2026 to a loss of $0.33 per share from expected earnings of $0.08, FY2026 to a loss of $0.23 from earnings of $0.03, FY2027 to a loss of $0.58 from earnings of $0.07, and FY2028 to earnings of $0.78 from $1.41. Estimates for Q1 2027, Q2 2028, and other future quarters were also reduced. While projections for Q4 2026 and Q2 2027 increased, the overall revisions indicate weaker profitability expectations. Zacks maintained a “Hold” rating. MarketBeat Novavax analyst estimates
• Negative Sentiment: Options activity showed unusually strong demand for downside protection, with traders purchasing 29,212 put options—172% above typical daily volume. The elevated put activity may signal increased hedging or bearish speculation. Novavax options activity article

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.